Form 4: Incyte Director Edmund Harrigan Acquires Shares as Compensation Under 10b5-1 Plan

Incyte Corp. Director Edmund Harrigan acquired 367 shares of common stock at $68.10 per share on June 30, 2025, as part of his quarterly director retainer fees under a Rule 10b5-1 plan.

Summary

• Edmund Harrigan, a Director of Incyte Corp. (INCY), acquired 367 shares of common stock.
• The transaction occurred on June 30, 2025, at a price of $68.10 per share.
• These shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan.
• The acquisition was in lieu of quarterly director retainer fees, pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.
• The acquired restricted shares are fully vested.
• Following this transaction, Edmund Harrigan beneficially owns 20,319 shares of Incyte common stock, which includes 2,518 shares from previously reported restricted stock units that have not yet vested.

Sentiment

Score: 7

Explanation: The filing indicates a routine, pre-planned stock acquisition by a director as part of compensation, which is generally a neutral to slightly positive signal as it aligns director interests with shareholders. The shares are fully vested, which is a positive for the director. No negative implications are present.

Positives

• Director Edmund Harrigan is receiving compensation in the form of company stock, aligning his interests with shareholders.
• The acquired restricted shares are fully vested, providing immediate ownership to the director.
• The transaction is part of a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary acquisition.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry where executive and director compensation often includes equity components to align leadership interests with long-term company performance and shareholder value. The use of a Rule 10b5-1 plan is common for pre-scheduled insider transactions.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as restricted shares, is a common industry standard across publicly traded companies, including those in the biotechnology sector like Incyte, aligning director incentives with shareholder interests.
• The use of Rule 10b5-1 plans for pre-scheduled stock acquisitions or sales by insiders is a widely adopted corporate governance practice, enhancing transparency and mitigating concerns about insider trading based on material non-public information.
• The specific value of shares acquired ($68.10 per share) reflects the market price at the time of the transaction, consistent with how equity compensation is typically valued.

Corporate Governance

Related Party Transactions

• The acquisition of 367 shares by Director Edmund Harrigan from Incyte Corp. as compensation constitutes a related party transaction, specifically an equity award to an insider.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director as compensation aligns the director's interests with those of shareholders, potentially fostering a greater focus on long-term stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Key Dates

Recommendation

Keywords

Incyte Corp, INCY, Edmund Harrigan, Director, Form 4, SEC filing, insider transaction, stock acquisition, restricted stock, 10b5-1 plan, corporate governance, executive compensation